<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000339</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-3-0010-4</org_study_id>
    <secondary_id>Y01-3-0010-4</secondary_id>
    <nct_id>NCT00000339</nct_id>
  </id_info>
  <brief_title>Infusion Laboratory: Protocol 3 (Risperidone) - 4</brief_title>
  <official_title>Infusion Laboratory: Protocol 3 (Risperidone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate clinical safety issues pertaining to risperidone,
      to cocaine and to its interaction, and to determine how pretreatment with risperidone
      modifies the subjective as well as physiological effects of cocaine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 1996</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evidence of change in neurotoxicity based on chore</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of drug craving</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>History, incidence and amount of drug use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Type and severity of stimulant withdrawal symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of study population</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Population incidence of symptoms of depression, po</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and intensity of drug use and sexual beh</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of change in subjective responses to coca</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical physiological response to cocaine challen</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree to which study medication influences change</measure>
  </primary_outcome>
  <enrollment>13</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the
        study and sign informed consent.

        Exclusion Criteria:

        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.
        Acute hepatitis. Other medical condtions that deem participation to be unsafe.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1996</verification_date>
  <lastchanged_date>August 16, 2005</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
